2023 Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study Group Transplant Complications Working Party (TCWP) 1st listed author Tapani Ruutu Journal Bone Marrow Transplant.
2023 Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Jaime Sanz Journal Bone Marrow Transplant.
2023 Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Rémi Tilmont Journal Bone Marrow Transplant.
2023 Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group Group GoCART Coalition 1st listed author Katerina Nezvalova-Henriksen Journal Bone Marrow Transplant.
2023 Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal J Hematol Oncol.
2023 Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2023 Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Br J Haematol.
2023 Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis Group Acute Leukemia Working Party (ALWP) 1st listed author Sjoerd J F Hermans Journal Hemasphere.
2023 GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Frédéric Baron Journal J Hematol Oncol.
2023 Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Sebastian Giebel Journal Am J Hematol.
2023 Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study Group Acute Leukemia Working Party (ALWP) 1st listed author Joshua A Fein Journal Blood Adv.
2023 Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial Group Chronic Malignancies Working Party (CMWP) 1st listed author Thomas Schroeder Journal Haematologica.